48,039 reports of this reaction
3.2% of all ADALIMUMAB reports
#3 most reported adverse reaction
ARTHRALGIA is the #3 most commonly reported adverse reaction for ADALIMUMAB, manufactured by AbbVie Inc.. There are 48,039 FDA adverse event reports linking ADALIMUMAB to ARTHRALGIA. This represents approximately 3.2% of all 1,482,766 adverse event reports for this drug.
Patients taking ADALIMUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among ADALIMUMAB users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for ADALIMUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 48,039 FDA reports for ADALIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.2% of all adverse event reports for ADALIMUMAB, making it one of the most commonly reported side effect.
If you experience arthralgia while taking ADALIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.